Drug intelligence / Profile preview

NPMW-peptide vaccine

Development stage: Phase 1
Modality: Peptides, Vaccines & Immunotherapeutics
Administration: Subcutaneous

Overview

NPMW-peptide vaccine is a peptide-based cancer vaccine designed to elicit immune responses against specific tumor antigens. The vaccine likely contains synthetic peptides that mimic epitopes of tumor-associated antigens, triggering the immune system to recognize and attack cancer cells. Peptide vaccines work by utilizing the human immune system rather than being pharmacologically active themselves. When administered subcutaneously, the peptides reach the lymph nodes via antigen-presenting cells and lymph flow, eventually inducing an immune response against cancer cells.

Targets

TLR3 (Toll-like receptor 3)MHC II (Major histocompatibility complex class II receptor)γδ TCR (T-cell receptor)

Beyond the preview

Go deeper on NPMW-peptide vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NPMW-peptide vaccine.

Explore the full profile